That was based on the phase III LIBERTY-AFRS-AIMS trial findings from 62 adults and kids with allergic fungal rhinosinusitis ...

GSK’s Exdensur receives China NMPA approval for the treatment of chronic rhinosinusitis with nasal polyps: London, UK Thursday, April 9, 2026, 09:00 Hrs [IST] GSK plc announced ...

Exdensur was approved in China as the first and only ultra-long-acting biologic for adult patients suffering from chronic rhinosinusitis with nasal polyps, according to a Wednesday filing. The disease ...

GSK (LSE:GSK) has received Chinese regulatory approval for Exdensur (depemokimab) as the first ultra long acting biologic for ...

Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate ...

The approval of depemokinab, of which Exdensur is the brand name, for chronic rhinosinusitis in addition to intranasal ...

Drugmaker GSK said on Wednesday that China's National Medical Products Administration has approved Exdensur as an add‑on ...

Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate ...

Sanofi’s lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP: Paris Wednesday, April 8, 2026, 09:00 Hrs [IST] Phase 2 studie ...

Pollen allergy symptoms include: -- Sneezing -- Runny nose and/or stuffy nose -- Itchy nose, eyes, ears, and mouth -- Swelling around the eyes -- Red, watery eyes -- Postnasal drip -- Shortness of ...